Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02720185 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With… | Phase 2 | terminated | Mar 25, 2016 | University of Wisconsin, Madison | Study terminated early due to COVID-19 related slow enrollment and funding | COVID-19 / pandemic |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT03874325 | Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | Phase 2 | terminated | Mar 14, 2019 | H. Lee Moffitt Cancer Center and Research Institute | lost funding | Funding |
| NCT00458796 | Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer… | N/A | terminated | Apr 11, 2007 | University of Leeds | Lower than expected recruitment | Enrollment / accrual |
| NCT02000596 | 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60… | Phase 2 | terminated | Dec 4, 2013 | University of Maryland, Baltimore | funding withdrawn by sponsor | Funding |
| NCT05005936 | Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast… | — | withdrawn | Aug 16, 2021 | M.D. Anderson Cancer Center | No participants Enrolled | Enrollment / accrual |
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast… | Phase 2 | withdrawn | Apr 17, 2020 | Academic and Community Cancer Research United | There are no patients enrolled on this study and all efforts are being discontinued | Enrollment / accrual |
| NCT03811262 | Comparison of Erector Spinae Plane Block With PECS II Block in Patients Undergoing Breast… | N/A | withdrawn | Jan 22, 2019 | University of Padova | Logistic reasons (Operating room performing the surgery investigated moved to another structure) | Other (stated, no rule matched) |
| NCT03261323 | Breast Reconstruction Following Breast Cancer in Very High Risk Patients | N/A | withdrawn | Aug 25, 2017 | Case Comprehensive Cancer Center | insufficient staff | Other (stated, no rule matched) |
| NCT05041751 | Myofascial Release or Trigger Point Injections for the Reduction of Post-Mastectomy Pain… | N/A | withdrawn | Sep 13, 2021 | M.D. Anderson Cancer Center | PI Left Institution | Investigator |
| NCT05037019 | SIGNAL During a COVID-19 Pandemic | N/A | withdrawn | Sep 8, 2021 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Surgery wait times during the COVID-19 pandemic were eventually reduced to pre-pandemic wait times.… | COVID-19 / pandemic |
| NCT03787303 | Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma(B-TREUH) | Phase 2 | terminated | Dec 26, 2018 | Aultman Health Foundation | Relocation of Principal Investigator | Investigator |
| NCT01067144 | Stanford Accelerated Recovery Trial (START) | Phase 3 | terminated | Feb 11, 2010 | Stanford University | Trial met futility stopping point | Efficacy / futility |
| NCT03448250 | Evaluating a Novel Web-based Intervention for Breast Cancer Survivors(OPTIMUNE) | N/A | terminated | Feb 28, 2018 | Technical University of Dortmund | Participant recruitment was stopped due to corona pandemic. | COVID-19 / pandemic |
| NCT05359874 | Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast…(DoT-FMI) | Phase 2 | withdrawn | May 4, 2022 | Technical University of Munich | application has been withdrawn | Other (stated, no rule matched) |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed…(0927GCC) | Phase 2 | terminated | Nov 4, 2010 | University of Maryland, Baltimore | low accrual | Enrollment / accrual |
| NCT05156463 | The PAI Trial for Breast and Colon Cancer Survivors | N/A | withdrawn | Dec 14, 2021 | Milton S. Hershey Medical Center | Award not yet received and PI is transferring to a different institution | Other (stated, no rule matched) |
| NCT04762901 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic… | Phase 1 | withdrawn | Feb 21, 2021 | Wake Forest University Health Sciences | Funding was terminated. | Funding |
| NCT03630653 | Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse(FIGARO) | N/A | terminated | Aug 15, 2018 | Institut Cancerologie de l'Ouest | The study was stopped prematurely due to insufficient recruitment | Enrollment / accrual |
| NCT03630809 | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | Phase 2 | terminated | Aug 15, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Quality of the data originating from prior versions of the protocol has been affected by protocol… | COVID-19 / pandemic |
| NCT02897050 | Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women… | Phase 2 | suspended | Sep 12, 2016 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | not stated | Not stated |
| NCT02482389 | Study of Preoperative Boost Radiotherapy | N/A | terminated | Jun 26, 2015 | Duke University | lack of enrollment | Enrollment / accrual |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT02850419 | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients(EURO-DIGNITY) | Phase 2 | withdrawn | Aug 1, 2016 | Imunon | Administrative | Other (stated, no rule matched) |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases… | Phase 1 | withdrawn | Sep 25, 2018 | Sorrento Therapeutics, Inc. | Unable to enroll subjects | Enrollment / accrual |
| NCT02269670 | Phase II Study of Everolimus Beyond Progression | Phase 2 | terminated | Oct 21, 2014 | Emory University | Slow to accrual | Enrollment / accrual |
| NCT02824575 | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast… | Phase 1 | terminated | Jul 6, 2016 | Montefiore Medical Center | Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are… | Other (stated, no rule matched) |
| NCT02936947 | Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or… | N/A | terminated | Oct 18, 2016 | Centre Hospitalier Universitaire Vaudois | due to Covid19 restrictions | COVID-19 / pandemic |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin… | Phase 2 | terminated | Dec 1, 2016 | G1 Therapeutics, Inc. | Primary Analysis and survival follow up completed per protocol. Not stopped due to safety concerns | Safety / toxicity |
| NCT04197999 | A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic… | Phase 1 | terminated | Dec 13, 2019 | GlycoMimetics Incorporated | After demonstrating the on target effect of GMI-1359 via pharmacodynamic markers (CXCR4 and… | COVID-19 / pandemic |
| NCT02696759 | Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant… | N/A | terminated | Mar 2, 2016 | University of Arkansas | PI left institution in 2019. Study was placed on hold at that time and will not be resuming. No… | Investigator |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine… | Phase 1 | withdrawn | Apr 28, 2015 | Washington University School of Medicine | Drugs not available | Other (stated, no rule matched) |
| NCT03733119 | ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative… | Phase 2 | terminated | Nov 7, 2018 | University of Wisconsin, Madison | Slow accrual | Enrollment / accrual |
| NCT02704312 | Dosimetric Comparison of Doses in Both Positions (Prone and Decubitus) for Patient With…(PROCUBITUS) | N/A | terminated | Mar 10, 2016 | University Hospital Center of Martinique | Start of the Principal Investigatoir | Other (stated, no rule matched) |
| NCT04856475 | Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in…(NeraBrain) | Phase 2 | withdrawn | Apr 23, 2021 | Jules Bordet Institute | Termination of collaboration with PUMA | Other (stated, no rule matched) |
| NCT02994914 | GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly…(GERABEL) | N/A | terminated | Dec 16, 2016 | Centre Hospitalier Universitaire de Saint Etienne | Low rythm of inclusions | Other (stated, no rule matched) |
| NCT01036113 | A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer(PEG-SN38) | Phase 2 | terminated | Dec 21, 2009 | Enzon Pharmaceuticals, Inc. | Program suspended and divested | Other (stated, no rule matched) |
| NCT03619044 | The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor…(REVER) | N/A | terminated | Aug 7, 2018 | Institut Claudius Regaud | Slow recruitment rate | Enrollment / accrual |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab…(VERU-111) | Phase 2 | withdrawn | Aug 17, 2021 | Veru Inc. | Decided to halt and will potentially reopen in the future. | Other (stated, no rule matched) |
| NCT02236572 | Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score | Phase 2 | terminated | Sep 10, 2014 | Yale University | Phase 2 of recruitment was contingent on 5 of 15 patients responding, which did not occur. | Enrollment / accrual |
| NCT04367467 | Effect of PARP Inhibitors on Glomerular Filtration Rate | — | terminated | Apr 29, 2020 | University of Pennsylvania | Due to constraints of COVID19, we were unable to recruit on-site for this study. | COVID-19 / pandemic |
| NCT00925652 | Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative…(ABCDE) | Phase 2 | terminated | Jun 22, 2009 | Dana-Farber Cancer Institute | The study was terminated early due to slow accrual. | Enrollment / accrual |
| NCT04296942 | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast… | Phase 1 | terminated | Mar 5, 2020 | National Cancer Institute (NCI) | One participant was accrued, and the study was stopped due to new safety data from the company for… | Safety / toxicity |
| NCT02204462 | FBnTP Imaging of Breast Cancer | Phase 1 | terminated | Jul 30, 2014 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Lock of funding | Funding |
| NCT02541188 | Genotype and Phenotype in Early Onset Breast Cancer in Young Women on the Two Shores of…(MediSein) | — | terminated | Sep 4, 2015 | University Hospital, Montpellier | not stated | Not stated |
| NCT04691999 | The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer(EFFECT-BC) | N/A | withdrawn | Dec 31, 2020 | Duke University | The PI is leaving Duke for a position in another state. | Other (stated, no rule matched) |
| NCT04038489 | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2-…(Breast 51) | Phase 2 | withdrawn | Jul 30, 2019 | University of Virginia | Lack of accrual | Enrollment / accrual |
| NCT01755208 | Light-Scattering Spectroscopy for Detection of Breast Cancer | N/A | terminated | Dec 24, 2012 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT03057743 | Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission… | — | terminated | Feb 20, 2017 | Abramson Cancer Center at Penn Medicine | Difficulty enrolling subjects | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jun 3, 2022source: clinicaltrials